Caxton Associates (New York)’s DaVita DVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$1.09M Sell
7,260
-3,998
-36% -$627K 0.03% 198
2024
Q3
$1.85M Buy
+11,258
New +$1.66M 0.07% 143
2024
Q2
Sell
-1,688
Closed -$233K 509
2024
Q1
$233K Buy
+1,688
New +$202K 0.01% 415
2022
Q3
Sell
-3,244
Closed -$259K 512
2022
Q2
$259K Buy
+3,244
New +$328K 0.03% 415
2020
Q4
Sell
-4,021
Closed -$344K 183
2020
Q3
$344K Buy
+4,021
New +$344K 0.04% 170
2020
Q1
Sell
-67,300
Closed -$5.05M 442
2019
Q4
$5.05M Buy
+67,300
New +$4.46M 0.69% 28
2019
Q1
Sell
-4,074
Closed -$210K 402
2018
Q4
$210K Buy
+4,074
New +$261K 0.03% 239
2014
Q2
Sell
-35,000
Closed -$2.41M 195
2014
Q1
$2.41M Buy
+35,000
New +$2.33M 0.15% 112

Other funds holding DVA

Caxton Associates (New York)'s DVA Position: Q4 2024 in Review

Caxton Associates (New York) reduced its DaVita (DVA) stake by 36% in Q4 2024, selling an estimated $627K and leaving 7,260 shares worth $1.09M. The position accounts for 0.03% of the portfolio, ranked #198.

Caxton Associates (New York) first reported a position in DVA in Q1 2014 and has held it in 8 quarters since. The position peaked at $5.05M in Q4 2019. 597 funds tracked by Wall St. Rank hold DVA as of Q4 2024.

  • Caxton Associates (New York) held 7,260 shares of DaVita worth $1.09M as of Q4 2024.
  • Caxton Associates (New York) sold 3,998 DaVita shares in Q4 2024, an estimated $627K.
  • DaVita made up 0.03% of Caxton Associates (New York)'s portfolio in Q4 2024, its #198 holding.
  • Caxton Associates (New York) first reported a position in DaVita in Q1 2014 and has held it in 8 quarters since.
  • Caxton Associates (New York)'s DaVita position peaked at $5.05M in Q4 2019.
  • 597 funds tracked by Wall St. Rank held DaVita as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.